Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities
Eun-mi Yu,1 Min Woo Hwang,2 Jeanny B Aragon-Ching1 1GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA; 2Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA, USACorrespondence: Jeanny B Aragon-Ching, Clinical Program Director of Genitourinary Cancers, Inova Schar Ca...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-11-01
|
Series: | Research and Reports in Urology |
Subjects: | |
Online Access: | https://www.dovepress.com/mechanistic-insights-on-localized-to-metastatic-prostate-cancer-transi-peer-reviewed-fulltext-article-RRU |
_version_ | 1797449045933817856 |
---|---|
author | Yu EM Hwang MW Aragon-Ching JB |
author_facet | Yu EM Hwang MW Aragon-Ching JB |
author_sort | Yu EM |
collection | DOAJ |
description | Eun-mi Yu,1 Min Woo Hwang,2 Jeanny B Aragon-Ching1 1GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA; 2Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA, USACorrespondence: Jeanny B Aragon-Ching, Clinical Program Director of Genitourinary Cancers, Inova Schar Cancer Institute, Associate Professor of Medical Education, University of Virginia School of Medicine, 8081 Innovation Park Drive, Fairfax, VA, USA, Tel +1-571-472-4724, Fax +1-571-472-1180, Email Jeanny.Aragon-Ching@inova.orgAbstract: Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable. Aberrant pathway activations of PI3K/AKT due to PTEN loss, epithelial–mesenchymal transition pathways, homologous recombination repair, and DNA repair pathway mechanisms of resistance and cross-talk lead to opportunities for therapeutic targeting in metastatic castration-resistant prostate cancer. This review focuses on mechanisms of progression and key trials that evaluate the drugs and combinations that exploit these pathways.Keywords: prostate cancer, metastasis, castration-resistant prostate cancer, epithelial mesenchymal transition, androgen receptor pathway inhibitors, poly-ADP ribose pathway inhibitors |
first_indexed | 2024-03-09T14:20:08Z |
format | Article |
id | doaj.art-f0f60806c2824e679bd77cdc1e79079b |
institution | Directory Open Access Journal |
issn | 2253-2447 |
language | English |
last_indexed | 2024-03-09T14:20:08Z |
publishDate | 2023-11-01 |
publisher | Dove Medical Press |
record_format | Article |
series | Research and Reports in Urology |
spelling | doaj.art-f0f60806c2824e679bd77cdc1e79079b2023-11-28T17:15:53ZengDove Medical PressResearch and Reports in Urology2253-24472023-11-01Volume 1551952988556Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic OpportunitiesYu EMHwang MWAragon-Ching JBEun-mi Yu,1 Min Woo Hwang,2 Jeanny B Aragon-Ching1 1GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA; 2Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA, USACorrespondence: Jeanny B Aragon-Ching, Clinical Program Director of Genitourinary Cancers, Inova Schar Cancer Institute, Associate Professor of Medical Education, University of Virginia School of Medicine, 8081 Innovation Park Drive, Fairfax, VA, USA, Tel +1-571-472-4724, Fax +1-571-472-1180, Email Jeanny.Aragon-Ching@inova.orgAbstract: Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable. Aberrant pathway activations of PI3K/AKT due to PTEN loss, epithelial–mesenchymal transition pathways, homologous recombination repair, and DNA repair pathway mechanisms of resistance and cross-talk lead to opportunities for therapeutic targeting in metastatic castration-resistant prostate cancer. This review focuses on mechanisms of progression and key trials that evaluate the drugs and combinations that exploit these pathways.Keywords: prostate cancer, metastasis, castration-resistant prostate cancer, epithelial mesenchymal transition, androgen receptor pathway inhibitors, poly-ADP ribose pathway inhibitorshttps://www.dovepress.com/mechanistic-insights-on-localized-to-metastatic-prostate-cancer-transi-peer-reviewed-fulltext-article-RRUprostate cancermetastasiscastration-resistant prostate cancerepithelial mesenchymal transitionandrogen receptor pathway inhibitorspoly-adp ribose pathway inhibitors |
spellingShingle | Yu EM Hwang MW Aragon-Ching JB Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities Research and Reports in Urology prostate cancer metastasis castration-resistant prostate cancer epithelial mesenchymal transition androgen receptor pathway inhibitors poly-adp ribose pathway inhibitors |
title | Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities |
title_full | Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities |
title_fullStr | Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities |
title_full_unstemmed | Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities |
title_short | Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities |
title_sort | mechanistic insights on localized to metastatic prostate cancer transition and therapeutic opportunities |
topic | prostate cancer metastasis castration-resistant prostate cancer epithelial mesenchymal transition androgen receptor pathway inhibitors poly-adp ribose pathway inhibitors |
url | https://www.dovepress.com/mechanistic-insights-on-localized-to-metastatic-prostate-cancer-transi-peer-reviewed-fulltext-article-RRU |
work_keys_str_mv | AT yuem mechanisticinsightsonlocalizedtometastaticprostatecancertransitionandtherapeuticopportunities AT hwangmw mechanisticinsightsonlocalizedtometastaticprostatecancertransitionandtherapeuticopportunities AT aragonchingjb mechanisticinsightsonlocalizedtometastaticprostatecancertransitionandtherapeuticopportunities |